JP2013540159A - モノアシルグリセロールリパーゼ阻害剤としてのピペリジン−４−イル−アゼチジンジアミド - Google Patents
モノアシルグリセロールリパーゼ阻害剤としてのピペリジン−４−イル−アゼチジンジアミド Download PDFInfo
- Publication number
- JP2013540159A JP2013540159A JP2013535086A JP2013535086A JP2013540159A JP 2013540159 A JP2013540159 A JP 2013540159A JP 2013535086 A JP2013535086 A JP 2013535086A JP 2013535086 A JP2013535086 A JP 2013535086A JP 2013540159 A JP2013540159 A JP 2013540159A
- Authority
- JP
- Japan
- Prior art keywords
- compounds
- phenyl
- thiazol
- group
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *C(CC1)(CCN1C(*)=O)C(C1)CN1C(*)=O Chemical compound *C(CC1)(CCN1C(*)=O)C(C1)CN1C(*)=O 0.000 description 1
- YIOJKTCNDDABKH-UHFFFAOYSA-N COC(c(cc1)cc(N)c1Nc(cc1)ccc1F)=O Chemical compound COC(c(cc1)cc(N)c1Nc(cc1)ccc1F)=O YIOJKTCNDDABKH-UHFFFAOYSA-N 0.000 description 1
- ITZAZWICCVIMBV-UHFFFAOYSA-N Cc1nc(cc(cc2)C(N(C3)CC3C(CC3)CCN3C(c3ncc[s]3)=O)=O)c2[n]1-c(cc1)ccc1F Chemical compound Cc1nc(cc(cc2)C(N(C3)CC3C(CC3)CCN3C(c3ncc[s]3)=O)=O)c2[n]1-c(cc1)ccc1F ITZAZWICCVIMBV-UHFFFAOYSA-N 0.000 description 1
- MAIGYOWJBPYLRC-UHFFFAOYSA-N Cc1nc(cc(cc2)C(O)=O)c2[n]1-c(cc1)ccc1F Chemical compound Cc1nc(cc(cc2)C(O)=O)c2[n]1-c(cc1)ccc1F MAIGYOWJBPYLRC-UHFFFAOYSA-N 0.000 description 1
- NDZSVPDVTLFJBU-UHFFFAOYSA-N Cc1nc(cc(cc2)C(OC)=O)c2[n]1-c(cc1)ccc1F Chemical compound Cc1nc(cc(cc2)C(OC)=O)c2[n]1-c(cc1)ccc1F NDZSVPDVTLFJBU-UHFFFAOYSA-N 0.000 description 1
- PPDMNMAECIVDQS-UHFFFAOYSA-N O=C(c1ncc[s]1)N(CC1)CCC1C1CNC1 Chemical compound O=C(c1ncc[s]1)N(CC1)CCC1C1CNC1 PPDMNMAECIVDQS-UHFFFAOYSA-N 0.000 description 1
- AUUCVVVVWBYHHP-UHFFFAOYSA-N OC(c1ccc(Cc2ccc(C(F)(F)F)cc2)cc1)=O Chemical compound OC(c1ccc(Cc2ccc(C(F)(F)F)cc2)cc1)=O AUUCVVVVWBYHHP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40587610P | 2010-10-22 | 2010-10-22 | |
| US61/405,876 | 2010-10-22 | ||
| PCT/US2011/057085 WO2012054716A1 (en) | 2010-10-22 | 2011-10-20 | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2013540159A true JP2013540159A (ja) | 2013-10-31 |
Family
ID=44993878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013535086A Pending JP2013540159A (ja) | 2010-10-22 | 2011-10-20 | モノアシルグリセロールリパーゼ阻害剤としてのピペリジン−４−イル−アゼチジンジアミド |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2629851A1 (pt) |
| JP (1) | JP2013540159A (pt) |
| KR (1) | KR20130142137A (pt) |
| CN (1) | CN103260703A (pt) |
| AR (1) | AR083542A1 (pt) |
| AU (1) | AU2011316970A1 (pt) |
| BR (1) | BR112013009858A2 (pt) |
| CA (1) | CA2815350A1 (pt) |
| IL (1) | IL225769A0 (pt) |
| RU (1) | RU2013123275A (pt) |
| TW (1) | TW201305136A (pt) |
| WO (1) | WO2012054716A1 (pt) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7413368B2 (ja) | 2018-09-28 | 2024-01-15 | ヤンセン ファーマシューティカ エヌ．ベー． | モノアシルグリセロールリパーゼ調節因子 |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| EP2970121B1 (en) * | 2013-03-15 | 2017-12-13 | Araxes Pharma LLC | Covalent inhibitors of kras g12c |
| US9745319B2 (en) | 2013-03-15 | 2017-08-29 | Araxes Pharma Llc | Irreversible covalent inhibitors of the GTPase K-Ras G12C |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| EP3087067B1 (en) | 2013-12-26 | 2018-10-24 | Takeda Pharmaceutical Company Limited | 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| AR102094A1 (es) | 2014-09-25 | 2017-02-01 | Araxes Pharma Llc | Inhibidores de proteínas kras con una mutación g12c |
| US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
| WO2016158956A1 (ja) | 2015-03-30 | 2016-10-06 | 武田薬品工業株式会社 | 複素環化合物 |
| BR112017021869A2 (pt) | 2015-04-10 | 2018-12-11 | Araxes Pharma Llc | compostos quinazolina substituídos e métodos de uso dos mesmos |
| WO2016168540A1 (en) | 2015-04-15 | 2016-10-20 | Araxes Pharma Llc | Fused-tricyclic inhibitors of kras and methods of use thereof |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356347A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356339A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| US10882847B2 (en) | 2015-09-28 | 2021-01-05 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058768A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017070256A2 (en) | 2015-10-19 | 2017-04-27 | Araxes Pharma Llc | Method for screening inhibitors of ras |
| CN108779097A (zh) | 2015-11-16 | 2018-11-09 | 亚瑞克西斯制药公司 | 包含取代的杂环基的2-取代的喹唑啉化合物及其使用方法 |
| US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| US10463753B2 (en) | 2016-02-19 | 2019-11-05 | Lundbeck La Jolla Research Center, Inc. | Radiolabeled monoacylglycerol lipase occupancy probe |
| WO2017172979A1 (en) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| AR108012A1 (es) | 2016-03-31 | 2018-07-04 | Takeda Pharmaceuticals Co | Derivados de azaespiro[3,4]octan-6-ona como inhibidores de magl |
| EP3438109B1 (en) | 2016-03-31 | 2021-08-25 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| US10280172B2 (en) | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3523289A1 (en) | 2016-10-07 | 2019-08-14 | Araxes Pharma LLC | Heterocyclic compounds as inhibitors of ras and methods of use thereof |
| CN110382482A (zh) | 2017-01-26 | 2019-10-25 | 亚瑞克西斯制药公司 | 稠合的杂-杂二环化合物及其使用方法 |
| WO2018140513A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| US11274093B2 (en) | 2017-01-26 | 2022-03-15 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| US10745385B2 (en) | 2017-05-25 | 2020-08-18 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| CN110869357A (zh) | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | 化合物及其用于治疗癌症的使用方法 |
| WO2018218069A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant kras, hras or nras |
| CN111148746B (zh) | 2017-09-29 | 2022-08-05 | 武田药品工业株式会社 | 杂环化合物 |
| CN109879797A (zh) * | 2019-01-10 | 2019-06-14 | 安徽昊帆生物有限公司 | N-苄基-四氢吡啶类化合物及其制备方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000026462A (ja) * | 1998-06-04 | 2000-01-25 | Pfizer Inc | ピペリドン |
| US20090269785A1 (en) * | 2008-04-25 | 2009-10-29 | Carsten Schubert | Crystal structure of monoacylglycerol lipase (mgll) |
| JP2010524908A (ja) * | 2007-04-18 | 2010-07-22 | サノフイ−アベンテイス | トリアゾロピリジンカルボキサミド誘導体およびトリアゾロピリミジンカルボキサミド誘導体、これらの調製、ならびにこれらの治療的使用 |
| WO2010115491A2 (en) * | 2009-04-02 | 2010-10-14 | Merck Patent Gmbh | Piperidine and piperazine derivatives as autotaxin inhibitors |
| WO2010124086A1 (en) * | 2009-04-22 | 2010-10-28 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8106208B2 (en) * | 2006-05-18 | 2012-01-31 | Albireo Ab | Benzamide compounds that act as NK receptor antagonists |
-
2011
- 2011-10-20 JP JP2013535086A patent/JP2013540159A/ja active Pending
- 2011-10-20 CA CA2815350A patent/CA2815350A1/en not_active Abandoned
- 2011-10-20 KR KR1020137012911A patent/KR20130142137A/ko not_active Application Discontinuation
- 2011-10-20 CN CN201180061809XA patent/CN103260703A/zh active Pending
- 2011-10-20 EP EP11784828.3A patent/EP2629851A1/en not_active Withdrawn
- 2011-10-20 AU AU2011316970A patent/AU2011316970A1/en not_active Abandoned
- 2011-10-20 WO PCT/US2011/057085 patent/WO2012054716A1/en active Application Filing
- 2011-10-20 RU RU2013123275/04A patent/RU2013123275A/ru not_active Application Discontinuation
- 2011-10-20 BR BR112013009858A patent/BR112013009858A2/pt not_active IP Right Cessation
- 2011-10-21 TW TW100138198A patent/TW201305136A/zh unknown
- 2011-10-24 AR ARP110103927A patent/AR083542A1/es not_active Application Discontinuation
-
2013
- 2013-04-15 IL IL225769A patent/IL225769A0/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000026462A (ja) * | 1998-06-04 | 2000-01-25 | Pfizer Inc | ピペリドン |
| JP2010524908A (ja) * | 2007-04-18 | 2010-07-22 | サノフイ−アベンテイス | トリアゾロピリジンカルボキサミド誘導体およびトリアゾロピリミジンカルボキサミド誘導体、これらの調製、ならびにこれらの治療的使用 |
| US20090269785A1 (en) * | 2008-04-25 | 2009-10-29 | Carsten Schubert | Crystal structure of monoacylglycerol lipase (mgll) |
| WO2010115491A2 (en) * | 2009-04-02 | 2010-10-14 | Merck Patent Gmbh | Piperidine and piperazine derivatives as autotaxin inhibitors |
| WO2010124086A1 (en) * | 2009-04-22 | 2010-10-28 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| GREENE, T. W. ET AL., PROTECTIVE GROUPS IN ORGANIC SYNTHESIS, THIRD EDITION, JPN6015027478, 1999, pages 518 - 525, ISSN: 0003111720 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7413368B2 (ja) | 2018-09-28 | 2024-01-15 | ヤンセン ファーマシューティカ エヌ．ベー． | モノアシルグリセロールリパーゼ調節因子 |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201305136A (zh) | 2013-02-01 |
| CN103260703A (zh) | 2013-08-21 |
| IL225769A0 (en) | 2013-06-27 |
| EP2629851A1 (en) | 2013-08-28 |
| BR112013009858A2 (pt) | 2016-07-26 |
| RU2013123275A (ru) | 2014-11-27 |
| AR083542A1 (es) | 2013-03-06 |
| WO2012054716A1 (en) | 2012-04-26 |
| CA2815350A1 (en) | 2012-04-26 |
| KR20130142137A (ko) | 2013-12-27 |
| AU2011316970A1 (en) | 2013-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013540159A (ja) | モノアシルグリセロールリパーゼ阻害剤としてのピペリジン−４−イル−アゼチジンジアミド | |
| EP2611774B1 (en) | Di-azetidinyl diamide as monoacylglycerol lipase inhibitors | |
| US8637498B2 (en) | Oxopiperazine-azetidine amides and oxodiazepine-azetidine amides as monoacylglycerol lipase inhibitors | |
| US8748417B2 (en) | Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors | |
| TWI495637B (zh) | 用作單醯基甘油脂肪酶抑制劑之雜芳族及芳族六氫吡基吖丁啶基醯胺（一） | |
| US8513423B2 (en) | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors | |
| TW201103914A (en) | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | |
| TW201313702A (zh) | 作為單醯基甘油脂酶抑制劑之側氧哌□－四氫吖唉醯胺及側氧二氮呯－四氫吖唉醯胺 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141020 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141128 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150625 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150707 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151007 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151109 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160216 |